ASCO advertising letters continue

FDA ad division letters cites Aventis for Taxotere (docetaxel) promotional brochure describing an unapproved indication and SkyePharma/Chiron for solicitation of off-label information requests for DepoCyt at the American Society of Clinical Oncology meeting in May. FDA has issued at least 11 letters regarding promotions at the meeting (1"The Pink Sheet" Aug. 6, p. 6)